PMID- 33429918
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210218
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jan 8
TI  - Improvement Effect of Metformin on Female and Male Reproduction in Endocrine 
      Pathologies and Its Mechanisms.
LID - 10.3390/ph14010042 [doi]
LID - 42
AB  - Metformin (MF), a first-line drug to treat type 2 diabetes mellitus (T2DM), alone 
      and in combination with other drugs, restores the ovarian function in women with 
      polycystic ovary syndrome (PCOS) and improves fetal development, pregnancy 
      outcomes and offspring health in gestational diabetes mellitus (GDM) and T2DM. MF 
      treatment is demonstrated to improve the efficiency of in vitro fertilization and 
      is considered a supplementary drug in assisted reproductive technologies. MF 
      administration shows positive effect on steroidogenesis and spermatogenesis in 
      men with metabolic disorders, thus MF treatment indicates prospective use for 
      improvement of male reproductive functions and fertility. MF lacks teratogenic 
      effects and has positive health effect in newborns. The review is focused on use 
      of MF therapy for restoration of female and male reproductive functions and 
      improvement of pregnancy outcomes in metabolic and endocrine disorders. The 
      mechanisms of MF action are discussed, including normalization of metabolic and 
      hormonal status in PCOS, GDM, T2DM and metabolic syndrome and restoration of 
      functional activity and hormonal regulation of the gonadal axis.
FAU - Shpakov, Alexander O
AU  - Shpakov AO
AD  - I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of Russian 
      Academy of Sciences, 194223 Saint Petersburg, Russia.
LA  - eng
GR  - 19-75-20122/Russian Science Foundation/
PT  - Journal Article
PT  - Review
DEP - 20210108
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC7826885
OTO - NOTNLM
OT  - diabetes mellitus
OT  - folliculogenesis
OT  - gestational diabetes mellitus
OT  - gonadotropin
OT  - in vitro fertilization
OT  - insulin
OT  - metformin
OT  - ovary
OT  - polycystic ovary syndrome
OT  - steroidogenesis
OT  - testes
COIS- The author declares no conflict of interest.
EDAT- 2021/01/13 06:00
MHDA- 2021/01/13 06:01
PMCR- 2021/01/08
CRDT- 2021/01/12 01:15
PHST- 2020/11/11 00:00 [received]
PHST- 2021/01/02 00:00 [revised]
PHST- 2021/01/06 00:00 [accepted]
PHST- 2021/01/12 01:15 [entrez]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/01/13 06:01 [medline]
PHST- 2021/01/08 00:00 [pmc-release]
AID - ph14010042 [pii]
AID - pharmaceuticals-14-00042 [pii]
AID - 10.3390/ph14010042 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2021 Jan 8;14(1):42. doi: 10.3390/ph14010042.